atorvastatin has been researched along with Pancreatic Neoplasms in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 9 (69.23) | 24.3611 |
| 2020's | 3 (23.08) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Hiari, Y; Al-Qirim, T; Alalawi, S; Arabiyat, S; Haj Hussein, B; Ikhmais, B; Kasabri, V | 1 |
| Jones, RD; Li, H; Liao, J; Sun, L; Tong, X; Xu, D; Yang, GY | 1 |
| Astsaturov, I; Cai, KQ; Chiaverelli, R; Cukierman, E; Fang, CY; Francescone, R; Franco-Barraza, J; Gabitova-Cornell, L; Goldman, AR; Golemis, EA; Handorf, EA; Hartman, TR; Khazak, V; Moffitt, RA; Nicolas, E; O'Reilly, AM; Ogier, C; Peri, S; Restifo, D; Shah, N; Sloma, I; Surumbayeva, A; Tan, Y; Weitz, N | 1 |
| Chen, J; Goodin, S; Li, DL; Ma, YR; Ma, YY; Ren, X; Wang, X; Xu, XT; Zhang, K; Zhao, DG; Zheng, X; Zhou, RP | 1 |
| Aouba, A | 1 |
| Anjali, CH; George, PD; Rajith, B; Ravindran, A; Sripriyalakshmi, S | 1 |
| Conney, AH; Cui, XX; Ding, N; Du, Z; Gao, Z; Hu, C; Huang, H; Lin, Y; Rabson, AB; Shih, WJ; Wei, X; Zheng, X | 1 |
| Li, Y; Liao, Q; Liu, Q; Lu, Z; Niu, Z; Wang, M; Yao, L; Zhao, Y; Zong, Y | 1 |
| Bang, S; Chung, MJ; Lee, HJ; Lee, HS; Lee, SH; Park, JY; Park, SW; Song, SY | 1 |
| Chang, JI; Huang, BZ; Li, E; Wu, BU; Xiang, AH | 1 |
| Mistafa, O; Stenius, U | 1 |
| Janakiram, NB; Lightfoot, S; Mohammed, A; Qian, L; Rao, CV; Steele, VE | 1 |
| Chung, YT; Li, H; Liao, J; Yan, L; Yang, AL; Yang, GY; Zhang, M; Zhang, W | 1 |
13 other study(ies) available for atorvastatin and Pancreatic Neoplasms
| Article | Year |
|---|---|
Selected Statins as Dual Antiproliferative-Antiinflammatory Compounds.
Topics: Anti-Inflammatory Agents; Atorvastatin; Caco-2 Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indomethacin; Pancreatic Neoplasms | 2022 |
Inhibition of mutant Kras and p53-driven pancreatic carcinogenesis by atorvastatin: Mainly via targeting of the farnesylated DNAJA1 in chaperoning mutant p53.
Topics: Animals; Atorvastatin; Carcinogenesis; Cell Line, Tumor; Disease Models, Animal; Farnesyltranstransferase; Gene Expression Regulation, Neoplastic; HSP40 Heat-Shock Proteins; Humans; Mice; Molecular Chaperones; Mutant Proteins; Pancreas; Pancreatic Neoplasms; Prenylation; Proto-Oncogene Proteins p21(ras); Quinolones; Tumor Suppressor Protein p53 | 2019 |
Cholesterol Pathway Inhibition Induces TGF-β Signaling to Promote Basal Differentiation in Pancreatic Cancer.
Topics: 3-Hydroxysteroid Dehydrogenases; Animals; Atorvastatin; Biosynthetic Pathways; Carcinoma, Pancreatic Ductal; Cell Differentiation; Cell Line, Tumor; Cholesterol, LDL; Epithelial-Mesenchymal Transition; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Mice, Inbred C57BL; Mice, Knockout; Pancreatic Neoplasms; Signal Transduction; Transforming Growth Factor beta; Xenograft Model Antitumor Assays | 2020 |
Effects of atorvastatin in combination with celecoxib and tipifarnib on proliferation and apoptosis in pancreatic cancer sphere-forming cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvastatin; Celecoxib; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Neoplastic Stem Cells; Pancreatic Neoplasms; Quinolones; Signal Transduction; Spheroids, Cellular | 2021 |
KRAS
Topics: Atorvastatin; Humans; Lung Neoplasms; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras) | 2017 |
BSA nanoparticle loaded atorvastatin calcium--a new facet for an old drug.
Topics: Adult; Animals; Anticholesteremic Agents; Antineoplastic Agents; Atorvastatin; Cattle; Cell Line, Tumor; Cell Survival; Hemolysis; Heptanoic Acids; Humans; Kinetics; Microscopy, Confocal; Microscopy, Electron, Scanning; Molecular Docking Simulation; Nanoparticles; Pancreatic Neoplasms; Pyrroles; Reactive Oxygen Species; Serum Albumin, Bovine; Spectrometry, Fluorescence; Spectroscopy, Fourier Transform Infrared; Time Factors | 2014 |
A triple combination of atorvastatin, celecoxib and tipifarnib strongly inhibits pancreatic cancer cells and xenograft pancreatic tumors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvastatin; Celecoxib; Cell Line, Tumor; Cell Proliferation; Female; Heptanoic Acids; Humans; Injections, Intraperitoneal; Mice; Mice, SCID; Neoplasms, Experimental; Pancreatic Neoplasms; Pyrazoles; Pyrroles; Quinolones; Sulfonamides; Xenograft Model Antitumor Assays | 2014 |
Atorvastatin (Lipitor) attenuates the effects of aspirin on pancreatic cancerogenesis and the chemotherapeutic efficacy of gemcitabine on pancreatic cancer by promoting M2 polarized tumor associated macrophages.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antimetabolites, Antineoplastic; Aspirin; Atorvastatin; Cell Line; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Macrophages; Male; Mice; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2016 |
Statin Use and Its Impact on Survival in Pancreatic Cancer Patients.
Topics: Adenocarcinoma; Aged; Anticholesteremic Agents; Atorvastatin; Dose-Response Relationship, Drug; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies; Risk Factors; Simvastatin; Survival Rate; Time Factors | 2016 |
Influence of Statins and Cholesterol on Mortality Among Patients With Pancreatic Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atorvastatin; California; Carcinoma, Pancreatic Ductal; Cholesterol, LDL; Deoxycytidine; Drug Prescriptions; Female; Gemcitabine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Pancreatic Neoplasms; Pravastatin; Proportional Hazards Models; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Survival Rate | 2017 |
Statins inhibit Akt/PKB signaling via P2X7 receptor in pancreatic cancer cells.
Topics: Apoptosis; Atorvastatin; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Fluorouracil; Gemcitabine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Pyrroles; Receptors, Purinergic P2; Receptors, Purinergic P2X7; RNA, Small Interfering; Signal Transduction | 2009 |
Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in p48Cre/+ LSL-KrasG12D/+ mice.
Topics: Animals; Apoptosis; Atorvastatin; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Proliferation; Cytokines; Disease Progression; Fluorescent Antibody Technique; Heptanoic Acids; Humans; Immunoenzyme Techniques; Integrases; Interferon-Stimulated Gene Factor 3, gamma Subunit; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutation; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Pyrroles; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Tumor Cells, Cultured | 2012 |
Atorvastatin inhibits pancreatic carcinogenesis and increases survival in LSL-KrasG12D-LSL-Trp53R172H-Pdx1-Cre mice.
Topics: Animals; Atorvastatin; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Epoxide Hydrolases; Heptanoic Acids; Homeodomain Proteins; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Ki-67 Antigen; Mice; Pancreas; Pancreatic Neoplasms; Phosphorylation; Prenylation; Proto-Oncogene Proteins c-raf; Proto-Oncogene Proteins p21(ras); Pyrroles; Trans-Activators; Transcriptome; Tumor Suppressor Protein p53 | 2013 |